Back to All Specialties
79 Clinical Tools

Hematology Calculators & Scores

Coagulation parameters, transfusion requirements, anemia classification, and thrombosis risk.

Hematology4ts-hit

4Ts Score for Heparin-Induced Thrombocytopenia

Differentiates patients with heparin-induced thrombocytopenia (HIT) from those with other causes of thrombocytopenia

Calculate Online
Hematologyabc-score

ABC Score for Massive Transfusion

Predicts the necessity for massive transfusion in trauma patients using clinical variables available at initial assessment

Calculate Online
Hematologyabsolute-eosinophil-count

Absolute Eosinophil Count

Absolute eosinophil count from WBC and differential.

Calculate Online
Hematologyabsolute-reticulocyte-count

Absolute Reticulocyte Count

Absolute reticulocyte count for anemia workup.

Calculate Online
Hematologyadjusted-gapss

Adjusted Gapss Antiphospholipid Syndrome Risk

Adjusted GAPSS: thrombotic risk in antiphospholipid syndrome.

Calculate Online
Hematologyalc

Absolute Lymphocyte Count (ALC)

Assesses lymphocyte count and predicts CD4 count in HIV patients

Calculate Online
Hematologyanc

Absolute Neutrophil Count (ANC)

Frequently used to assess febrile neutropenia in chemotherapy patients, by calculating the total number of mature and immature neutrophils

Calculate Online
Hematologyball-score-rr-cll

BALL Score for Relapsed/Refractory CLL

Assesses prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. The BALL Score (β2-microglobulin, Anemia, LDH, Last Therapy) helps estimate survival outcomes in patients with R/R-CLL who require further treatment with targeted therapies.

Calculate Online
Hematologybinet-stage-cll

Binet Stage for Chronic Lymphocytic Leukaemia

Binet staging for chronic lymphocytic leukemia.

Calculate Online
Hematologybinet-staging-cll

Binet Staging System for Chronic Lymphocytic Leukemia (CLL)

Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions

Calculate Online
Hematologyblood-volume-calculation

Blood Volume Calculation

Calculates total blood volume, red blood cell volume, and plasma volume using Nadler equations based on age, sex, height, weight, and hematocrit

Calculate Online
Hematologycll-ipi

International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.

Calculate Online
Hematologycns-ipi

Central Nervous System International Prognostic Index (CNS-IPI)

Prognostic scoring system that predicts the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy. Helps identify patients who may benefit from CNS-directed prophylaxis and guides treatment planning decisions.

Calculate Online
Hematologycorrected-count-increment

Corrected Count Increment (CCI) for Platelet Transfusion

Assesses adequacy of response to platelet transfusion by measuring the expected increase in platelets adjusted for patient size and platelet dose

Calculate Online
Hematologycorrected-reticulocyte-count

Corrected Reticulocyte Count

Reticulocyte percentage corrected for anemia.

Calculate Online
Hematologycryoprecipitate-dosing

Cryoprecipitate Dosing for Fibrinogen Replacement

Calculates the required dose of cryoprecipitate units needed to achieve target fibrinogen levels in patients with fibrinogen deficiency or hypofibrinogenemia

Calculate Online
Hematologydash-prediction-score

DASH Prediction Score for Recurrent VTE

Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.

Calculate Online
Hematologydipss-plus

DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis

Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters

Calculate Online
Hematologydlbcl-ipi

International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.

Calculate Online
Hematologydli-volume

Donor Lymphocyte Infusion (DLI) Volume

Estimates total blood volume to process by apheresis to produce appropriate DLI dosage

Calculate Online
Hematologyduval-cibmtr-score-aml-survival

Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival

Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.

Calculate Online
Hematologyeln-2022-aml-risk

ELN 2022 AML Risk Stratification

ELN 2022 genetic risk classification for acute myeloid leukemia.

Calculate Online
Hematologyeutos-score

EUTOS Score for Chronic Myelogenous Leukemia (CML)

Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.

Calculate Online
Hematologyflipi

Follicular Lymphoma International Prognostic Index (FLIPI)

Estimates overall survival in patients with follicular lymphoma based on 5 adverse prognostic factors to stratify patients into risk groups for treatment planning.

Calculate Online
Hematologyganzoni-equation-iron-deficiency

Ganzoni Equation for Iron Deficiency Anemia

Assesses total body iron deficit for iron replacement therapy. Calculates the precise amount of iron needed to replenish body iron stores and correct hemoglobin levels in patients with iron deficiency anemia.

Calculate Online
Hematologyganzoni-iron-deficit

Ganzoni Iron Deficit

Calculates total body iron deficit to guide parenteral iron replacement dosing.

Calculate Online
Hematologygelf-criteria

Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance

Calculate Online
Hematologygeneva-vte-prophylaxis

Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis

Predicts the need for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients by assessing risk factors to identify patients who would benefit from thromboprophylaxis versus those at low risk who may not require anticoagulation

Calculate Online
Hematologygipss-primary-myelofibrosis

GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis

The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.

Calculate Online
Hematologyhas-bled-score

HAS-BLED Score for Major Bleeding Risk

Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.

Calculate Online
Hematologyhct-ci

Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)

Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.

Calculate Online
Hematologyhematotox-score

CAR-HEMATOTOX Score

Pre-lymphodepletion risk stratification for prolonged hematologic toxicity and severe infections after CAR-T therapy.

Calculate Online
Hematologyhemorr2hages

HEMORR₂HAGES Score for Major Bleeding Risk

Quantifies hemorrhage risk in elderly patients with atrial fibrillation on anticoagulation therapy. The score helps clinicians assess bleeding risk when considering anticoagulation for stroke prevention in AF patients.

Calculate Online
Hematologyhep-hit

HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia

Pre-test clinical scoring model for heparin-induced thrombocytopenia (HIT) based on broad expert opinion. Helps guide clinical decisions regarding therapy and reduces unnecessary use of alternative anticoagulants.

Calculate Online
Hematologyheparin-weight-based-dosing

Weight-Based Heparin Dosing (Raschke)

Weight-based unfractionated heparin bolus and infusion per the Raschke nomogram, with absolute maximum caps.

Calculate Online
Hematologyherdoo2

HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE

Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.

Calculate Online
Hematologyhscore

HScore for Reactive Hemophagocytic Syndrome

Estimates the risk of having reactive hemophagocytic syndrome (RHS) based on clinical, laboratory, and histologic findings. Uses nine variables to provide a probability score ranging from <1% to >99% for RHS diagnosis.

Calculate Online
Hematologyicc-pmf-diagnostic-criteria

International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)

Diagnoses primary myelofibrosis according to the International Consensus Classification (ICC) criteria published in 2022. This systematic diagnostic framework distinguishes between prefibrotic (early) and overt (fibrotic) stages of primary myelofibrosis using morphological, genetic, and clinical criteria. The ICC criteria refine the WHO classification system by providing better diagnostic specificity for myeloproliferative neoplasms. The diagnosis requires all three major criteria plus at least one minor criterion, confirmed in two consecutive determinations. This classification facilitates accurate diagnosis, appropriate staging, prognostic assessment, and treatment planning for patients with suspected primary myelofibrosis. The tool is particularly valuable for hematologists and pathologists in differentiating PMF from other myeloproliferative neoplasms and establishing precise diagnostic categorization.

Calculate Online
Hematologyicc-systemic-mastocytosis-diagnostic-criteria

International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis

Diagnoses systemic mastocytosis according to the International Consensus Classification (ICC) criteria using morphological, immunophenotypic, and molecular parameters. The ICC criteria refine the WHO classification system with enhanced diagnostic specificity for mast cell disorders.

Calculate Online
Hematologyimpede-vte

IMPEDE-VTE

Predicts risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. The IMPEDE-VTE score was developed and validated in large cohorts (4,446 patients in derivation, 4,256 in validation) to identify multiple myeloma patients at highest risk for VTE during treatment. Patients with multiple myeloma have a 9-fold increased risk of VTE compared to the general population. This validated score helps clinicians identify patients who would benefit most from thromboprophylaxis and is incorporated into National Comprehensive Cancer Network (NCCN) guidelines. The model stratifies patients into low, intermediate, and high-risk categories with cumulative 6-month VTE incidences ranging from 3.8-5.0% (low risk) to 24.1-40.5% (high risk) across validation studies.

Calculate Online
Hematologyimprove-bleeding-risk-score

IMPROVE Bleeding Risk Score

Assesses bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. The IMPROVE Bleeding Risk Score was developed from an international observational database of 15,156 patients across 52 hospitals in 12 countries to predict major bleeding and clinically relevant non-major bleeding within 14 days of admission. The cumulative incidence of major and non-major but clinically relevant in-hospital bleeding within 14 days of admission was 3.2%. This validated tool helps clinicians identify patients at high risk for bleeding complications and assess the risk-benefit ratio of pharmacological thromboprophylaxis. Patients with scores ≥7 have significantly greater rates of major bleeding (3.9% vs 1.2%) and should be carefully evaluated before anticoagulation.

Calculate Online
Hematologyimprove-vte-risk-score

IMPROVE Risk Score for Venous Thromboembolism (VTE)

Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.

Calculate Online
Hematologyimprovedd-vte-risk-score

IMPROVEDD Risk Score for Venous Thromboembolism (VTE)

Predicts 77-day risk of acute venous thromboembolism (VTE) in hospitalized medical patients by incorporating D-dimer levels into the IMPROVE Risk Score. The IMPROVEDD (IMPROVE + D-dimer) score enhances the original IMPROVE VTE risk assessment by adding D-dimer ≥2× upper limit of normal as an additional risk factor worth 2 points. This validated clinical prediction tool was developed from the APEX trial involving 7,441 hospitalized medically ill patients. The addition of D-dimer significantly improves VTE risk discrimination and reclassification compared to the original IMPROVE score. An IMPROVEDD score ≥2 identifies patients with heightened VTE risk through 77 days, helping clinicians make more informed decisions about extended thromboprophylaxis duration in acutely ill medical patients.

Calculate Online
Hematologyips-e-cll

International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)

Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.

Calculate Online
Hematologyipss-r

Revised International Prognostic Scoring System (IPSS-R) for MDS

Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.

Calculate Online
Hematologyisth-dic-criteria

ISTH Criteria for Disseminated Intravascular Coagulation (DIC)

Diagnoses overt disseminated intravascular coagulation (DIC) based on laboratory parameters. This scoring system was developed by the International Society on Thrombosis and Haemostasis (ISTH) as a standardized approach to DIC diagnosis using readily available laboratory tests. Use only in patients with clinical suspicion for DIC in appropriate clinical settings.

Calculate Online
Hematologyisth-overt-dic

ISTH Overt DIC Score

Diagnoses overt disseminated intravascular coagulation in patients with an underlying compatible condition.

Calculate Online
Hematologyisth-scc-bleeding-assessment-tool

ISTH-SCC Bleeding Assessment Tool

Assesses bleeding symptoms in patients with inherited bleeding disorders. This standardized questionnaire was developed by the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) to evaluate 14 different bleeding symptoms and identify patients who may have inherited bleeding disorders requiring further investigation.

Calculate Online
Hematologyjaam-dic-score

JAAM DIC Score

Japanese Association for Acute Medicine DIC score for early diagnosis in critical care.

Calculate Online
Hematologykhorana-score

Khorana Score (Chemotherapy-Associated VTE Risk)

Predicts risk of venous thromboembolism in ambulatory cancer patients starting chemotherapy.

Calculate Online
Hematologymalt-lymphoma-prognostic-index

MALT Lymphoma Prognostic Index (MALT-IPI)

Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.

Calculate Online
Hematologymantle-cell-lymphoma-international-prognostic-index

Mantle Cell Lymphoma International Prognostic Index (MIPI)

Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.

Calculate Online
Hematologymascc-risk-index-febrile-neutropenia

MASCC Risk Index for Febrile Neutropenia

Identifies febrile neutropenia patients at low risk for poor outcome including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications. Developed by Multinational Association for Supportive Care in Cancer (MASCC) to guide outpatient vs inpatient management decisions.

Calculate Online
Hematologymaternal-fetal-hemorrhage-rhd-immune-globulin-dosage

Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage

Calculates amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN). Essential for preventing maternal anti-D antibody formation when Rh-negative mother is exposed to Rh-positive fetal blood.

Calculate Online
Hematologymaximum-allowable-blood-loss-without-transfusion

Maximum Allowable Blood Loss (ABL) Without Transfusion

Estimates maximum allowable blood loss intraoperatively before transfusion should be considered. Essential for surgical blood loss management and transfusion decision-making based on patient weight, age group, initial hemoglobin, and acceptable final hemoglobin levels.

Calculate Online
Hematologymayo-alliance-prognostic-system-maps-score

Mayo Alliance Prognostic System (MAPS) Score

Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.

Calculate Online
Hematologymentzer-index

Mentzer Index

Differentiates beta thalassemia trait from iron deficiency anemia using MCV and RBC count. A simple screening tool that helps distinguish between these two common causes of microcytic anemia.

Calculate Online
Hematologymichigan-picc-risk

Michigan Risk Score for PICC-Related Thrombosis

Predicts risk of deep vein thrombosis (DVT) in patients with peripherally inserted central catheter (PICC)

Calculate Online
Hematologymipss70

Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)

Stratifies risk for patients with overt primary myelofibrosis (PMF) using clinical, laboratory, and molecular genetic parameters. This enhanced prognostic system incorporates high molecular risk mutations to improve risk stratification beyond traditional clinical factors.

Calculate Online
Hematologymultiple-myeloma-diagnostic-criteria

Multiple Myeloma Diagnostic Criteria (IMWG)

Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.

Calculate Online
Hematologymultiple-myeloma-iss

Multiple Myeloma International Staging System (ISS)

Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.

Calculate Online
Hematologymultiple-myeloma-response-criteria

Multiple Myeloma Response Criteria (IMWG)

Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.

Calculate Online
Hematologymysec-pm

Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)

Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.

Calculate Online
Hematologynccn-ipi

National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)

Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.

Calculate Online
Hematologyneutrophil-lymphocyte-ratio

Neutrophil-Lymphocyte Ratio (NLR) Calculator

Calculates neutrophil-lymphocyte ratio

Calculate Online
Hematologyplasmic-score

PLASMIC Score — TTP Risk Stratification

The PLASMIC score predicts severe ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura. 7 items, 1 point each. Total 0-7.

Calculate Online
Hematologyplatelet-lymphocyte-ratio

Platelet-to-Lymphocyte Ratio (PLR)

PLR is a systemic inflammation marker: platelets divided by lymphocytes (same units). Reported as a continuous value; no single validated cutoff.

Calculate Online
Hematologypv-thrombosis-risk

Polycythemia Vera Thrombosis Risk

ELN/Tefferi risk stratification for thrombosis in polycythemia vera: high risk if age >= 60 or prior thrombosis.

Calculate Online
Hematologyr-iss

Revised International Staging System (R-ISS) for Multiple Myeloma

Myeloma staging combining ISS, LDH and high-risk cytogenetics.

Calculate Online
Hematologyreticulocyte-production-index

Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)

Assesses bone marrow response to anemia by correcting reticulocyte count for degree of anemia and maturation time

Calculate Online
Hematologysokal

Sokal Score (CML Prognosis)

CML prognostic score at diagnosis: <0.8 low, 0.8-1.2 intermediate, >1.2 high risk.

Calculate Online
Hematologystfr-index

Soluble Transferrin Receptor / Ferritin Index

sTfR/log(ferritin) index helps distinguish iron deficiency from anemia of chronic disease.

Calculate Online
Hematologytotal-blood-volume-nadler

Total Blood Volume (Nadler)

Estimates total blood volume (BV) in adults using the Nadler formula (1962): sex-specific equations from height (m) and weight (kg). Result in liters; multiply by 1000 for mL.

Calculate Online
Hematologytransferrin-saturation

Transferrin Saturation

Transferrin saturation for iron deficiency evaluation.

Calculate Online
Hematologyvillalta-score

Villalta Score for Post-thrombotic Syndrome (PTS)

Diagnoses and stratifies severity of post-thrombotic syndrome in patients with history of deep venous thrombosis (DVT). The score combines patient-reported symptoms with physician-assessed clinical signs to provide standardized PTS evaluation.

Calculate Online
Hematologyvte-bleed-score

VTE-BLEED Score

Assesses bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). This validated risk score enables better stratification of bleeding risk during stable anticoagulation after a first VTE episode. Unlike bleeding risk scores derived from atrial fibrillation patients, the VTE-BLEED score is specifically designed for VTE patients who have different comorbidity profiles and risk factors.

Calculate Online
Hematologywho-polycythemia-vera-criteria

WHO Diagnostic Criteria for Polycythemia Vera (2016)

World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.

Calculate Online
Hematologywho-systemic-mastocytosis-criteria

WHO Diagnostic Criteria for Systemic Mastocytosis (2016)

World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.

Calculate Online
Hematologywpss-mds

WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome

Assesses prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement. The WPSS provides dynamic prognostic assessment throughout disease course and stratifies patients into five risk groups.

Calculate Online

Clinical Decision Support (CDS) Notice & Legal Disclaimer

All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.